Biologics now command over 70% of the Orphan Drugs Market, driven by gene therapies, enzyme replacements, and monoclonal antibodies. Approved gene therapies for rare diseases grew from 7 in 2020 to 23 by late 2024, with 40+ candidates in pivotal trials. These therapies address previously untreatable conditions like spinal muscular atrophy and sickle cell disease. Parenteral administration dominates due to infusion requirements, though oral formulations are gaining traction. AI-enabled adaptive trials have compressed Phase II timelines by up to 45%, reducing development costs. While premium pricing—often exceeding USD 1.5 million per patient—raises payer concerns, outcomes-based contracts are improving access.

Q1. What share do biologics hold in the Orphan Drugs Market? A. Biologics accounted for approximately 70.2% of market revenue in 2025.

Q2. How many approved gene therapies exist for rare diseases? A. 23 approved gene therapies were available by year-end 2024.

Q3. What is the fastest-growing route of administration? A. Oral therapies are projected to grow at a 12.82% CAGR through 2035.